[Drug induced hepatotoxicity in targeted therapy for lung cancer]

Zhongguo Fei Ai Za Zhi. 2014 Sep 20;17(9):685-8. doi: 10.3779/j.issn.1009-3419.2014.09.08.
[Article in Chinese]

Abstract
in English, Chinese

Targeted drugs aimed at driver gene, such as Gefitinib, Erlotinib and Crizotinib, have an irreplaceable position in the therapy of advanced non-small cell lung cancer. These drugs bring benefit to patients, however, higher hepatotoxicity is also presented. Now, drug induced hepatotoxicity and its mechanism are reviewed.

针对驱动基因的靶向药物吉非替尼、厄洛替尼及克唑替尼等在晚期非小细胞肺癌治疗中有着不可替代的地位，然而此类药物给患者带来益处的同时也出现较高的肝脏毒性，现就其肝脏毒性及机制作一综述。

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Liver / drug effects*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Molecular Targeted Therapy / adverse effects*
  • Polymorphism, Genetic
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Protein Kinase Inhibitors

Grants and funding

本研究受浙江省自然科学基金重点项目（No.LZ13H160001）资助